Podium to Practice: ESMO® 2026 – GU: LITESPARK-011
OR
Studies / Trials Discussed
3587O – Final analysis of the phase 3 LITESPARK-011 study: belzutifan (bel) plus lenvatinib (len) versus cabozantinib (cabo) for advanced renal cell carcinoma (RCC) after anti–PD-(L)1 therapy
Speakers
Explore more from your favourite experts – click their name to access their entire library of content.
Studies/trials discussed:
3587O – Final analysis of the phase 3 LITESPARK-011 study: belzutifan (bel) plus lenvatinib (len) versus cabozantinib (cabo) for advanced renal cell carcinoma (RCC) after anti–PD-(L)1 therapy
Login to view content
PLease Enter Your Email to view Content
Pre-Video Survey
By continuing to watch the video, you consent to receiving a post-view survey by email.